As expected, international medical device major, Smith & Nephew plc (SNN - Snapshot Report) recently completed the acquisition of Texas-based Healthpoint Biotherapeutics for $782 million in cash. The deal was initiated in the last week of November 2012. This acquisition is a part of its strategy to expand further in the advanced wound management market in which the company is already growing above the market rate.
For the past few years, Healthpoint has been working successfully in acute, chronic, and burn-related wound care management and is currently a big name among the biopharmaceutical companies. The company’s Collagenase Santyl ointment is an important contributor to growth in the commercial platform. Besides, the company developed an advanced cell therapy, HP802-247, which successfully completed the phase 2b study in 2011. In September 2012, the North American phase 3 trial for the same was initiated.
Smith & Nephew considers this acquisition as an important step toward creating a strong portfolio in bioactives, the fastest growing area of advanced wound management. According to the company, this will be possible by bringing material revenues from a fast growing product range, an attractive pipeline and the commercial and R&D capabilities of Healthpoint, thereby providing Smith & Nephew with new growth opportunities for the next decade and beyond.
The Advanced Wound Management segment supplies a range of products and clinical support services for the treatment of chronic and acute skin wounds. Earlier, with the acquisition of BlueSky, Smith & Nephew had gained access to a series of products that treat chronic wounds, such as diabetic ulcers, post-operative, and hard-to-heal wounds using Negative Pressure Wound Therapy ("NPWT") and a range of negative pressure pumps and wound dressing kits.
At the end of the third quarter of fiscal 2012, the company’s Advanced Wound Management (AWM) revenue stood at $254 million (contributing 27% to its total revenues), up 4% year over year. Amid the tough economic conditions in the U.S. and Europe, this 4% increase in revenue was encouraging. Industry-wide growth in the U.S. and Europe was 2%.
Besides, we expect this acquisition to perfectly fit with its new strategic framework with five priorities to drive growth in the forthcoming period. This framework includes focus on established markets, growth in emerging markets, innovation, simplification of the operating model and supplementing organic growth through acquisitions. Despite several headwinds, Smith & Nephew aims to improve its performance going forward on the back of a strong product pipeline and higher acquisition related investments. The company expects to achieve above market growth in Advanced Wound Management in the upcoming quarters.
Notably, Smith & Nephew has maintained a strong cash position over the past several quarters. The company exited the third quarterwith cash and cash equivalents of $417 million, considerably higher than $265 million in the year-ago quarter.Trading cash flow (defined as cash generated from operations less capital expenditure but before acquisition related costs and restructuring and rationalization costs) was $264 million in the quarter, reflecting a trading profit to cash conversion ratio of 128% compared with the year-ago ratio of 102%.
However, the competitive landscape remains intense as Smith & Nephew faces stiff competition from larger players like Stryker (SYK - Analyst Report), Johnson & Johnson’s (JNJ - Analyst Report) DePuy and Zimmer (ZMH - Analyst Report). We have a ‘Neutral’ recommendation on Smith & Nephew. The stock retains a Zacks #3 Rank (Hold) in the short term.